Clinical Trials Browser

Not yet recruiting × Carcinoma, Non-Small-Cell Lung × tislelizumab × Clear all

NCT07468071 2026-03-12

KontRASt-R

Phase 1/2 Not yet recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07432984 2026-02-25

FMT-LUNG

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06977828 2025-06-29

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06883552 2025-03-19

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06607926 2024-09-23

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung